• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同的残基介导过氧化物酶体增殖物激活受体γ配体结合域中1-O-油酰基溶血磷脂酸和罗格列酮的识别。

Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma.

作者信息

Tsukahara Tamotsu, Tsukahara Ryoko, Yasuda Satoshi, Makarova Natalia, Valentine William J, Allison Patrick, Yuan Hongbin, Baker Daniel L, Li Zaiguo, Bittman Robert, Parrill Abby, Tigyi Gabor

机构信息

Department of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

出版信息

J Biol Chem. 2006 Feb 10;281(6):3398-407. doi: 10.1074/jbc.M510843200. Epub 2005 Dec 1.

DOI:10.1074/jbc.M510843200
PMID:16321982
Abstract

Here we showed that a naturally occurring ether analog of lysophosphatidic acid, 1-O-octadecenyl-2-hydroxy-sn-glycero-3-phosphate (AGP), is a high affinity partial agonist of the peroxisome proliferator-activated receptor gamma (PPARgamma). Binding studies using the PPARgamma ligand binding domain showed that [32P]AGP and [3H]rosiglitazone (Rosi) both specifically bind to PPARgamma and compete with each other. [32P]AGP bound PPARgamma with an affinity (Kdapp 60 nm) similar to that of Rosi. However, AGP displaced approximately 40% of bound [3H]Rosi even when applied at a 2000-fold excess. Activation of PPARgamma reporter gene expression by AGP and Rosi showed similar potency, yet AGP-mediated activation was approximately 40% that of Rosi. A complex between AGP and PPARgamma was generated using molecular modeling based on a PPARgamma crystal structure. AGP-interacting residues were compared with Rosi-interacting residues identified within the Rosi-PPARgamma co-crystal complex. These comparisons showed that the two ligands occupy partially overlapping positions but make different hydrogen bonding and ion pairing interactions. Site-specific mutants of PPARgamma were prepared to examine individual ligand binding. H323A and H449A mutants showed reduced binding of Rosi but maintained binding of AGP. In contrast, the R288A showed reduced AGP binding but maintained Rosi binding. Finally, alanine replacement of Tyr-473 abolished binding and activation by Rosi and AGP. These observations indicate that the endogenous lipid mediator AGP is a high affinity ligand of PPARgamma but that it binds via interactions distinct from those involved in Rosi binding. These distinct interactions are likely responsible for the partial PPARgamma agonism of AGP.

摘要

在此我们证明,溶血磷脂酸的一种天然存在的醚类似物,1-O-十八碳烯基-2-羟基-sn-甘油-3-磷酸(AGP),是过氧化物酶体增殖物激活受体γ(PPARγ)的高亲和力部分激动剂。使用PPARγ配体结合结构域的结合研究表明,[32P]AGP和[3H]罗格列酮(Rosi)均特异性结合PPARγ并相互竞争。[32P]AGP以与Rosi相似的亲和力(Kdapp 60 nm)结合PPARγ。然而,即使以2000倍过量应用,AGP也只能取代约40%结合的[3H]Rosi。AGP和Rosi对PPARγ报告基因表达的激活显示出相似的效力,但AGP介导的激活约为Rosi的40%。基于PPARγ晶体结构,通过分子建模生成了AGP与PPARγ之间的复合物。将AGP相互作用残基与在Rosi-PPARγ共晶体复合物中鉴定出的Rosi相互作用残基进行了比较。这些比较表明,两种配体占据部分重叠的位置,但形成不同的氢键和离子配对相互作用。制备了PPARγ的位点特异性突变体以检查单个配体的结合情况。H323A和H449A突变体显示Rosi的结合减少,但维持了AGP的结合。相反,R288A显示AGP结合减少,但维持了Rosi的结合。最后,用丙氨酸取代Tyr-473消除了Rosi和AGP的结合及激活。这些观察结果表明,内源性脂质介质AGP是PPARγ的高亲和力配体,但它通过与Rosi结合所涉及的相互作用不同的相互作用进行结合。这些不同的相互作用可能是AGP对PPARγ产生部分激动作用的原因。

相似文献

1
Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma.不同的残基介导过氧化物酶体增殖物激活受体γ配体结合域中1-O-油酰基溶血磷脂酸和罗格列酮的识别。
J Biol Chem. 2006 Feb 10;281(6):3398-407. doi: 10.1074/jbc.M510843200. Epub 2005 Dec 1.
2
Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.溶血磷脂酸诱导的动脉壁重构:PPARγ的必需性,但不是 LPA1 或 LPA2 GPCR。
Cell Signal. 2009 Dec;21(12):1874-84. doi: 10.1016/j.cellsig.2009.08.003. Epub 2009 Aug 23.
3
Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.硝酰化脂肪酸对过氧化物酶体增殖物激活受体 γ 的共价加合:选择性配体活性和抗糖尿病信号转导作用。
J Biol Chem. 2010 Apr 16;285(16):12321-33. doi: 10.1074/jbc.M109.091512. Epub 2010 Jan 22.
4
T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.T2384,一种具有独特过氧化物酶体增殖物激活受体γ结合特性的新型抗糖尿病药物。
J Biol Chem. 2008 Apr 4;283(14):9168-76. doi: 10.1074/jbc.M800104200. Epub 2008 Feb 7.
5
Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers.抗糖尿病药物罗格列酮通过将转录重新分配至PPARγ驱动的增强子来重塑脂肪细胞转录组。
Genes Dev. 2014 May 1;28(9):1018-28. doi: 10.1101/gad.237628.114.
6
Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.过氧化物酶体增殖物激活受体γ及噻唑烷二酮类口服抗糖尿病药物对人胰岛素基因转录的抑制作用
Br J Pharmacol. 2009 Jul;157(5):736-45. doi: 10.1111/j.1476-5381.2009.00208.x. Epub 2009 Mar 26.
7
N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.N-乙酰法呢基半胱氨酸是一种新型的过氧化物酶体增殖物激活受体 γ 配体,具有体外和体内部分激动剂和完全激动剂活性。
J Biol Chem. 2011 Dec 2;286(48):41626-41635. doi: 10.1074/jbc.M111.257915. Epub 2011 Oct 6.
8
Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2.溶血磷脂酸通过溶血磷脂酸1受体依赖性下调过氧化物酶体增殖物激活受体γ2来抑制脂肪细胞分化。
J Biol Chem. 2005 Apr 15;280(15):14656-62. doi: 10.1074/jbc.M412585200. Epub 2005 Feb 14.
9
Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo.罗格列酮激活过氧化物酶体增殖物激活受体γ(PPARγ)可在体外和体内抑制胰岛素样生长因子调节系统的组成部分。
Endocrinology. 2007 Feb;148(2):903-11. doi: 10.1210/en.2006-1121. Epub 2006 Nov 22.
10
Study of new interactions of glitazone's stereoisomers and the endogenous ligand 15d-PGJ2 on six different PPAR gamma proteins.研究新型手性格列酮立体异构体与内源性配体 15d-PGJ2 在六种不同的 PPARγ 蛋白上的新相互作用。
Biochem Pharmacol. 2017 Oct 15;142:168-193. doi: 10.1016/j.bcp.2017.07.012. Epub 2017 Jul 15.

引用本文的文献

1
Endogenous ether lipids differentially promote tumor aggressiveness by regulating the SK3 channel.内源性醚脂通过调节 SK3 通道差异促进肿瘤侵袭性。
J Lipid Res. 2024 May;65(5):100544. doi: 10.1016/j.jlr.2024.100544. Epub 2024 Apr 18.
2
Emerging roles of lysophosphatidic acid receptor subtype 5 (LPAR5) in inflammatory diseases and cancer.溶血磷脂酸受体亚型 5(LPAR5)在炎症性疾病和癌症中的新兴作用。
Pharmacol Ther. 2023 May;245:108414. doi: 10.1016/j.pharmthera.2023.108414. Epub 2023 Apr 13.
3
Molecular basis of unique specificity and regulation of group VIA calcium-independent phospholipase A (PNPLA9) and its role in neurodegenerative diseases.
家族 VIA 钙非依赖型磷酸酶 A(PNPLA9)的独特特异性和调控的分子基础及其在神经退行性疾病中的作用。
Pharmacol Ther. 2023 May;245:108395. doi: 10.1016/j.pharmthera.2023.108395. Epub 2023 Mar 27.
4
Peroxisomal regulation of energy homeostasis: Effect on obesity and related metabolic disorders.过氧化物酶体对能量平衡的调节:对肥胖和相关代谢紊乱的影响。
Mol Metab. 2022 Nov;65:101577. doi: 10.1016/j.molmet.2022.101577. Epub 2022 Aug 19.
5
Each phospholipase A type exhibits distinct selectivity toward sn-1 ester, alkyl ether, and vinyl ether phospholipids.每种磷脂酶 A 类型对 sn-1 酯、烷基醚和乙烯基醚磷脂均表现出不同的选择性。
Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Jan;1867(1):159067. doi: 10.1016/j.bbalip.2021.159067. Epub 2021 Oct 9.
6
Binding of Per- and Polyfluoro-alkyl Substances to Peroxisome Proliferator-Activated Receptor Gamma.全氟和多氟烷基物质与过氧化物酶体增殖物激活受体γ的结合
ACS Omega. 2021 Jun 4;6(23):15103-15114. doi: 10.1021/acsomega.1c01304. eCollection 2021 Jun 15.
7
Plasmalogens, platelet-activating factor and beyond - Ether lipids in signaling and neurodegeneration.醚脂类在信号转导和神经退行性变中的作用:血小板激活因子和其他相关物质。
Neurobiol Dis. 2020 Nov;145:105061. doi: 10.1016/j.nbd.2020.105061. Epub 2020 Aug 28.
8
Regulation of Tumor Immunity by Lysophosphatidic Acid.溶血磷脂酸对肿瘤免疫的调节作用
Cancers (Basel). 2020 May 10;12(5):1202. doi: 10.3390/cancers12051202.
9
Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer.肝癌中溶血磷脂酸代谢与信号传导的失调
Cancers (Basel). 2019 Oct 23;11(11):1626. doi: 10.3390/cancers11111626.
10
Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.溶血磷脂酸 2 型受体激动剂在靶向药物研发中具有广阔的治疗潜力。
J Lipid Res. 2019 Mar;60(3):464-474. doi: 10.1194/jlr.S091744. Epub 2019 Jan 28.